Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Clovis Oncology (CLVS) Stock Price

Media stories about Clovis Oncology (NASDAQ:CLVS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clovis Oncology earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.9389792166695 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Get Clovis Oncology alerts: Year-to-date (YTD) to Watch: Clovis Oncology, Inc. (NASDAQ:CLVS), Impac Mortgage Holdings, Inc. (NYSE:IMH … (stocksnewspoint.com) AstraZeneca, Merck eye wider cancer drug use after study success (uk.reuters.com) AstraZeneca, Merck eye $1 billion boost from cancer drug success (reuters.com) Notable Gainers and Laggards: Heron Therapeutics, Inc., (NASDAQ: HRTX), Clovis Oncology, Inc., (NASDAQ: CLVS) (globalexportlines.com) The Player of Success: Clovis Oncology, Inc. (CLVS) (toptelegraph.com)

CLVS has been the topic of a number of recent analyst reports. Credit Suisse Group set a $86.00 price target on Clovis Oncology and gave the stock a “buy” rating in a report on Friday, April 6th. Bank of America dropped their price target on Clovis Oncology from $90.00 to $55.52 and set a “buy” rating on the stock in a report on Monday, April 9th. SunTrust Banks lifted their price target on Clovis Oncology to $90.00 and gave the stock a “buy” rating in a report on Monday, April 9th. Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Tuesday, May 1st. Finally, Royal Bank of Canada restated a “buy” rating and issued a $73.00 target price on shares of Clovis Oncology in a research note on Tuesday, June 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $84.09.

Shares of CLVS traded up $2.29 during mid-day trading on Tuesday, hitting $47.43. The stock had a trading volume of 19,804 shares, compared to its average volume of 1,078,054. The firm has a market cap of $2.39 billion, a PE ratio of -9.26 and a beta of 1.37. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.55 and a quick ratio of 5.74. Clovis Oncology has a 52 week low of $41.31 and a 52 week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by ($0.18). The company had revenue of $18.50 million during the quarter, compared to analysts’ expectations of $18.34 million. Clovis Oncology had a negative net margin of 545.80% and a negative return on equity of 79.02%. Clovis Oncology’s revenue for the quarter was up 164.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) earnings per share. sell-side analysts anticipate that Clovis Oncology will post -5.33 earnings per share for the current fiscal year.

In other news, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction on Monday, April 9th. The stock was sold at an average price of $60.02, for a total value of $270,090.00. Following the completion of the transaction, the director now directly owns 7,618 shares in the company, valued at $457,232.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.20% of the stock is currently owned by insiders.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.